153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC).

MLA

Conte, P. F., et al. “153P HER2DX Risk-Score in the Context of the PREDICT Online-Tool: A Correlative Analysis of the Short-HER Clinical Trial in Early-Stage HER2-Positive (HER2+) Breast Cancer (BC).” Annals of Oncology, vol. 33, Sept. 2022, pp. S609–10. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.07.188.

APA

Conte, P. F., Pare Brunet, L., Brasó-Maristany, F., Chic, N., Martinez Saez, O., Dieci, M. V., Marin, M., Guarneri, V., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C. M., & Prat, A. (2022). 153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC). Annals of Oncology, 33, S609–S610. https://doi.org/10.1016/j.annonc.2022.07.188

Chicago

Conte, P.F., L. Pare Brunet, F. Brasó-Maristany, N. Chic, O. Martinez Saez, M.V. Dieci, M. Marin, et al. 2022. “153P HER2DX Risk-Score in the Context of the PREDICT Online-Tool: A Correlative Analysis of the Short-HER Clinical Trial in Early-Stage HER2-Positive (HER2+) Breast Cancer (BC).” Annals of Oncology 33 (September): S609–10. doi:10.1016/j.annonc.2022.07.188.